Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tivozanib and Durvalumab in Advanced HCC
NCT03970616Phase 2Terminated
- Sponsor
- AVEO Oncology
- Start
- Sep 2019
- Primary completion
- Apr 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tivozanib in hepatocellular carcinoma (HCC), sponsored by AVEO Oncology. Primary endpoint: Incidence of Treatment Emergent Adverse Events at 24 months. Started Sep 2019; status: terminated.
02
Drugs
tivozanib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03970616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03970616.